Angiogenesis Inhibitors and Stimulators: A Global Strategic Business Report
San Jose, CA (Vocus/PRWEB) February 23, 2011
Given the pivotal role that it plays in the growth of tumors, angiogenesis has become one of the most sought after targets for developing treatments in the area of oncology. The global pharmaceutical market, during the past decade, witnessed the introduction of several anti-angiogenesis drugs that aid in arresting tumor growth in various types of cancers. Additionally, several more compounds are in various stages of clinical development. Industry participants are focusing on development of drugs that target several signaling and regulatory molecules that include growth factors such as Vascular Endothelial Growth Factors, PDGF (Platelet-Derived Growth Factors) and FGF (Fibroblast Growth Factors), transcription factors, receptor tyrosine kinases, among others. Continuing robust growth of marketed drugs and a promising pipeline of drugs vying to demonstrate superior efficacy in various cancers bode substantial growth in the market in the following years.
Angiogenesis is a phenomenon that is associated with a diverse set of conditions such as cancers, age-related macular degeneration, psoriasis and rheumatoid arthritis. However, cancers have been the main focal area for most drug developers, given the potential for significant expansion in this market. AMD has taken a distant second spot in the targeted indications for anti-angiogenesis drugs. Research and development of novel angiogenic drugs is highest in the field of cancer treatment. The underlying focus of anti-angiogenic therapy lies in gradually shrinking the existing tumors, and prophylatically inhibit formation of metastatic lesions. The anti-angiogenic drugs are associated with low degrees of eliciting side effects, owing to their mechanism of action (that is, they affect genetically stable normal endothelial cells).
The US represents the single largest regional market for angiogenesis inhibitors and stimulators worldwide, as stated by the new market research report on Angiogenesis Inhibitors And Stimulators. Europe trails behind the US market. Avastin (bevacizumab), developed by Roche and Genentech, is a humanized monoclonal antibody, targeted against VEGF (Vascular Endothelial Growth Factor), and is the largest selling angiogenesis inhibitor drug worldwide. The product represents the first in its class to yield successful results against cancer. Avastin bagged US FDA approval in 2004, for application as first-line therapy (in combination with intravenous 5-Fluorouracil), in treating patients suffering from metastatic colorectal cancer. Studies have demonstrated that Avastin, when used in combination with standard chemotherapy, conferred a median overall survival benefit of nearly 2 years in metastatic colorectal cancer patients, and further established its safety and efficacy in several other indications.
Avastin is the first anti-angiogenesis inhibitor in the world, and was established to delay progression of tumor growth by way of targeting VEGF tyrosine kinase, the key factor responsible in vascular growth. Several drugs with anti-angiogenic activities have subsequently forayed into the market. Tyrosine kinase inhibitors or RTK inhibitors such as Novartis’ Gleevec, OSI Pharmaceuticals’s Tarceva, AstraZeneca’s Iressa, and ImClone’s Erbitux were the other key drugs that entered into the market, subsequent to Avastin. Most of these drugs act by interfering signaling between growth factors and receptors known for assisting tumor growth, thereby leading to indirect inhibition of angiogenesis.
Major players profiled in the report include AstraZeneca Plc., Celgene Corporation, Chugai Pharmaceutical Co. Ltd., EntreMed Inc., Eyetech Inc., Genentech Inc., ImClone Systems Inc., Novartis, Pfizer Inc., Roche, among others.
The research report titled “Angiogenesis Inhibitors and Stimulators: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the angiogenesis inhibitors and stimulators markets, current market trends, key growth drivers, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for angiogenesis inhibitors and stimulators market for the years 2009 through 2015 for the following geographic markets - US, Europe and Rest of World; and by the following market segments – Angiogenesis Inhibitors and Angiogenesis Stimulators. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Angiogenesis_Inhibitors_And_Stimulators_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #